報價延遲最少15分鐘:2025/05/10 07:06 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.7 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.46/--
|
|
企業價值
77.97M
|
| 資產負債 |
|
每股賬面淨值
1.64
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
37.87M
|
|
每股收益
2.91
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/10 07:06 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ. |